

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A biologically active composition ~~of matter~~ comprising ceruloplasmin and a serum-derived composition (SDF) having a low molecular weight, being electrically charged at acidic pH and having absorption at 280 nm.
2. (Currently Amended) The biologically active composition ~~of matter~~ of claim 1, wherein a concentration of said serum-derived composition is selected capable of inducing terminal cell differentiation of leukemic cells.
3. (Currently Amended) The biologically active composition ~~of matter~~ of claim 1, wherein a concentration of said serum-derived composition is selected capable of inducing loss of proliferation and self cell renewal in leukemic cells.
4. (Currently Amended) The biologically active composition ~~of matter~~ of claim 1, wherein a concentration of said serum-derived composition is selected capable of stimulating the proliferation of early, normal progenitor cells.
5. (Currently Amended) The biologically active composition ~~of matter~~ of claim 1, wherein a concentration of said serum-derived composition is selected capable of inhibiting enhanced angiogenesis.
6. (Original) A pharmaceutical composition comprising, as active ingredients, ceruloplasmin and a serum-derived composition (SDF) having a low molecular weight, being electrically charged at acidic pH and having absorption at 280 nm, and a pharmaceutically acceptable additive.
7. (Original) The pharmaceutical composition of claim 6, wherein a concentration of said serum-derived composition is selected capable of inhibiting enhanced angiogenesis.

8. (Original) The pharmaceutical composition of claim 6, wherein a concentration of said serum-derived composition is selected capable of inducing remission in tumor tissue.

9. (Original) The pharmaceutical composition of claim 6, wherein a concentration of said serum-derived composition is selected capable of expanding hematopoietic normal stem and progenitor bone marrow transplants.

10-16. (Cancelled).